{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.0","upperLimit":"20.3","value":"4.4"},{"comment":"NA = Median DOR was not reached because there were not enough events, DOR upper 95% confidence limit was undefined because the DOR rate was not low enough at the time of the cut-off date.","groupId":"OG001","lowerLimit":"15.9","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"57"}],"units":"Participants"}],"description":"For participants who demonstrated a confirmed response (CR or PR) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until disease progression or death. Per protocol, the DOR was to be censored at the date of the last tumor assessment for participants who had progressed or died after 2 or more missed visits, who had started a new anti-cancer treatment, who were lost to follow-up, or who had an ongoing response. DOR was assessed in all participants based on BICR and was analyzed using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received paclitaxel 175 mg/m\\^2 intravenously (IV) or docetaxel 75 mg/m\\^2 IV or vinflunine 320 mg/m\\^2 IV, on Day 1 of each 3-week cycle (Q3W). Eligible participants who experienced disease progression may have been able to switch over to receive pembrolizumab 200 mg IV Q3W for up to 35 treatment administrations (up to approximately 2 years).","id":"OG000","title":"Control"},{"description":"Participants received pembrolizumab 200 mg IV on Day 1 Q3W. Eligible participants who stopped pembrolizumab with Stable Disease (SD) or better but progressed after discontinuation may have been able to initiate a second course of pembrolizumab 200 mg IV Q3W for up to 17 cycles (up to approximately 1 additional year).","id":"OG001","title":"Pembrolizumab"}],"paramType":"MEDIAN","populationDescription":"The analysis population consisted of all randomized participants who demonstrated a confirmed response (CR or PR) per RECIST 1.1, regardless of whether or not they received study treatment. Participants were included in the treatment group to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Through final analysis database cut-off date of 26-Oct-2017 (Up to approximately 34 months)","title":"DOR Per RECIST 1.1 - All Participants","type":"SECONDARY","unitOfMeasure":"Months"}